Pulse Biosciences Inc PLSE
News
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)